Kimberly Yonkers to Surveys and Questionnaires
This is a "connection" page, showing publications Kimberly Yonkers has written about Surveys and Questionnaires.
Connection Strength
1.401
-
Chang G, Ondersma SJ, Blake-Lamb T, Gilstad-Hayden K, Orav EJ, Yonkers KA. Identification of substance use disorders among pregnant women: A comparison of screeners. Drug Alcohol Depend. 2019 12 01; 205:107651.
Score: 0.381
-
Yonkers KA, Gotman N, Kershaw T, Forray A, Howell HB, Rounsaville BJ. Screening for prenatal substance use: development of the Substance Use Risk Profile-Pregnancy scale. Obstet Gynecol. 2010 Oct; 116(4):827-833.
Score: 0.203
-
Smith MV, Gotman N, Lin H, Yonkers KA. Do the PHQ-8 and the PHQ-2 accurately screen for depressive disorders in a sample of pregnant women? Gen Hosp Psychiatry. 2010 Sep-Oct; 32(5):544-8.
Score: 0.200
-
Wallenstein GV, Blaisdell-Gross B, Gajria K, Guo A, Hagan M, Kornstein SG, Yonkers KA. Development and validation of the Premenstrual Symptoms Impact Survey (PMSIS): a disease-specific quality of life assessment tool. J Womens Health (Larchmt). 2008 Apr; 17(3):439-50.
Score: 0.171
-
Smith MV, Costello D, Yonkers KA. Clinical correlates of prescription opioid analgesic use in pregnancy. Matern Child Health J. 2015 Mar; 19(3):548-56.
Score: 0.069
-
Yonkers KA, Howell HB, Allen AE, Ball SA, Pantalon MV, Rounsaville BJ. A treatment for substance abusing pregnant women. Arch Womens Ment Health. 2009 Aug; 12(4):221-7.
Score: 0.046
-
Yonkers KA, Smith MV, Lin H, Howell HB, Shao L, Rosenheck RA. Depression screening of perinatal women: an evaluation of the healthy start depression initiative. Psychiatr Serv. 2009 Mar; 60(3):322-8.
Score: 0.046
-
Spoozak L, Gotman N, Smith MV, Belanger K, Yonkers KA. Evaluation of a social support measure that may indicate risk of depression during pregnancy. J Affect Disord. 2009 Apr; 114(1-3):216-23.
Score: 0.044
-
Yonkers KA, Lin H, Howell HB, Heath AC, Cohen LS. Pharmacologic treatment of postpartum women with new-onset major depressive disorder: a randomized controlled trial with paroxetine. J Clin Psychiatry. 2008 Apr; 69(4):659-65.
Score: 0.043
-
Borenstein JE, Dean BB, Leifke E, Korner P, Yonkers KA. Differences in symptom scores and health outcomes in premenstrual syndrome. J Womens Health (Larchmt). 2007 Oct; 16(8):1139-44.
Score: 0.041
-
Dean BB, Borenstein JE, Knight K, Yonkers K. Evaluating the criteria used for identification of PMS. J Womens Health (Larchmt). 2006 Jun; 15(5):546-55.
Score: 0.038
-
Yonkers KA, Pearlstein T, Rosenheck RA. Premenstrual disorders: bridging research and clinical reality. Arch Womens Ment Health. 2003 Nov; 6(4):287-92.
Score: 0.031
-
Borenstein JE, Dean BB, Endicott J, Wong J, Brown C, Dickerson V, Yonkers KA. Health and economic impact of the premenstrual syndrome. J Reprod Med. 2003 Jul; 48(7):515-24.
Score: 0.031
-
Yonkers KA, Ramin SM, Rush AJ, Navarrete CA, Carmody T, March D, Heartwell SF, Leveno KJ. Onset and persistence of postpartum depression in an inner-city maternal health clinic system. Am J Psychiatry. 2001 Nov; 158(11):1856-63.
Score: 0.027
-
Gariepy A, Lundsberg LS, Vilardo N, Stanwood N, Yonkers K, Schwarz EB. Pregnancy context and women's health-related quality of life. Contraception. 2017 May; 95(5):491-499.
Score: 0.020
-
Bernstein IH, Rush AJ, Yonkers K, Carmody TJ, Woo A, McConnell K, Trivedi MH. Symptom features of postpartum depression: are they distinct? Depress Anxiety. 2008; 25(1):20-6.
Score: 0.011